title: Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
abstract: Evaluate long-term cisplatin-induced ototoxicity in women treated for malignant ovarian germ cell tumors (MOGCT).
  
  
  
  Seventy-four women treated for MOGCT in Norway (1980-2009) were analyzed: 41 had received cisplatin-based chemotherapy (CBCT) ("Cases") and 33 had no CBCT ("Controls"). Median follow-up was 15years. Hearing was assessed by pure tone audiometry and by the SCIN questionnaire. Air conduction thresholds were reported as absolute hearing thresholds and age-adjusted thresholds. Absolute and age-adjusted hearing loss were defined as thresholds of >20dB at any frequency. Tinnitus was evaluated using the Tinnitus Handicap Inventory. Serum Platinum Concentration (SPC) was determined.
  
  
  
  Absolute hearing loss was identified in 21 Cases (51%) and 24 Controls (73%). After adjusting for age, only 9 Cases (22%) and 5 Controls (15%) remained. Age-adjusted hearing thresholds at 4, 6 and 8kHz were slightly but significantly higher in Cases compared to Controls. Subjective hearing loss was reported by 27% of Cases and 21% of Controls, who were significantly older. Elevated SPC values were detected up to 20years after CBCT, but SPC did not correlate significantly with age-adjusted hearing loss. The rate of tinnitus was similar in Cases and Controls.
  
  
  
  Long-term MOGCT survivors treated with CBCT have small but significant reductions in age-adjusted hearing thresholds at 4, 6 and 8kHz versus Controls. Approximately one in four women experienced subjective hearing loss. To avoid overestimation of clinically relevant cisplatin-induced ototoxicity, absolute hearing thresholds should be age-adjusted and compared to an age-matched control group.
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Rikshospitalet, Oslo University Hospital, Norway.
authors.forename: Jakob
authors.initials: J
authors.lastname: Skalleberg
authors.affiliation: Department of Gynecological Oncology, Radiumhospitalet, Oslo University Hospital, Norway.
authors.forename: Olesya
authors.initials: O
authors.lastname: Solheim
authors.affiliation: National Resource Center for Late Effects after Cancer Treatment, Radiumhospitalet, Oslo University Hospital, Norway. Electronic address: sopfos@ous-hf.no.
authors.forename: Sophie D
authors.initials: SD
authors.lastname: Fosså
authors.affiliation: Department of Health Science and Biostatistics, Høgskolen i Oslo og Akershus, Norway.
authors.forename: Milada Cvancarova
authors.initials: MC
authors.lastname: Småstuen
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Rikshospitalet, Oslo University Hospital, Norway.
authors.forename: Terje
authors.initials: T
authors.lastname: Osnes
authors.affiliation: Department of Clinical Pharmacology, St Olav University Hospital, Trondheim, Norway.
authors.forename: Per Ole M
authors.initials: POM
authors.lastname: Gundersen
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Rikshospitalet, Oslo University Hospital, Norway.
authors.forename: Marie
authors.initials: M
authors.lastname: Bunne
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001301:Audiometry, Pure-Tone; D001761:Bleomycin / Q000008:administration & dosage; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D034381:Hearing Loss / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D008137:Longitudinal Studies; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010052:Ovariectomy; D010984:Platinum / Q000097:blood; D014747:Vinblastine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D001761:Bleomycin; D010984:Platinum; D014747:Vinblastine; D005047:Etoposide; D002945:Cisplatin